Aiding in diagnosing progressive multifocal leukoencephalopathy due to JC virus
This test is not to be used as a diagnostic tool for Creutzfeldt-Jakob disease
This test is not recommended for screening asymptomatic patients
For more information see Meningitis/Encephalitis Panel Algorithm.
Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
JCV DNA
JCV Qualitative DNA
John Cunningham Virus (JCV)
Polyomavirus
Progressive Multifocal Leukoencephalopathy (PML)
For more information see Meningitis/Encephalitis Panel Algorithm.
CSF
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Preferred: 12 x 75-mm screw cap vial
Acceptable: Sterile screw cap vial
Container/Tube: Sterile vial
Specimen Volume: 0.5 mL
Collection Instructions: Do not centrifuge.
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.
0.3 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 7 days | |
Frozen | 7 days |
Aiding in diagnosing progressive multifocal leukoencephalopathy due to JC virus
This test is not to be used as a diagnostic tool for Creutzfeldt-Jakob disease
This test is not recommended for screening asymptomatic patients
For more information see Meningitis/Encephalitis Panel Algorithm.
JC virus (JCV), a member of the genus Polyomavirus, is a small nonenveloped DNA-containing virus. Primary infection occurs in early childhood, with a prevalence of greater than 80%.(1) The virus is latent but can reactivate in immunosuppressed patients, especially those with AIDS.
JCV is recognized as the etiologic agent of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system.(2,3) Histologic examination of brain biopsy tissue may reveal characteristic pathologic changes localized mainly in oligodendrocytes and astrocytes. Detection of JCV DNA by polymerase chain reaction (PCR) (target gene, large T antigen) in the cerebrospinal fluid specimens of patients with suspected PML infection has replaced the need for biopsy tissue for laboratory diagnosis.(4) Importantly, the PCR test is specific with no cross-reaction with BK virus, a closely related polyomavirus.
Negative
Detection of JC virus (JCV) DNA supports the clinical diagnosis of progressive multifocal leukoencephalopathy due to JCV.
A negative result does not rule out the possibility of JC virus (JCV) infection.
The reference value in cerebrospinal fluid is "negative" for this assay, although JCV DNA may be detectable in the absence of clinical symptoms in certain patient populations.(5,6) However, this assay is only to be used for patients with appropriate neurological and neuroradiological features of progressive multifocal leukoencephalopathy and is not indicated for screening asymptomatic patients.
The following data supports the use of this assay for clinical testing.
Accuracy:
Twenty-six negative cerebrospinal fluid (CSF) specimens were spiked with JC virus (JCV)-positive control plasmid at the limit of detection (approximately 10 targets/mcL). The 26 spiked specimens were run in a blinded manner with 14 negative (non-spiked) specimens. One hundred percent of the spiked specimens were positive, and 100% of the non-spiked specimens were negative.
Analytical Sensitivity/Limit of Detection:
The lower limit of detection of this assay is 10 DNA target copies per mcL in CSF.
Analytical Specificity:
No polymerase chain reaction (PCR) signal was obtained from the extracts of 15 viral isolates that may cause similar symptoms or be found in the CSF, including herpes simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus, human herpesvirus (HHV)-6, HHV-7, HHV-8, enterovirus, mumps, adenovirus, BK virus, and Simian virus 40 (SV40).
Precision:
Interassay precision was 100% and intraassay precision was 100%.
Reference Range:
The reference range in CSF is "negative" for this assay.
Reportable Range:
This is a qualitative assay, and the results are reported as either negative or positive for targeted JCV DNA.
1. Safak M, Khalili K. An overview: human polyomavirus JC virus and its associated disorders. J Neurovirol. 2003;9 Suppl 1:3-9
2. Khalili K, White MK. Human demyelinating disease and the polyomavirus JCV. Mult Scler. 2006;12(2):133-142
3. Ahsan N, Shah KV. Polyomaviruses and human diseases. Adv Exp Med Biol. 2006;577:1-18
4. Romero JR, Kimberlin DW. Molecular diagnosis of viral infections of the central nervous system. Clin Lab Med. 2003;23(4):843-865
5. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361(11):1067-1074
6. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy donors. J Infect Dis. 2009;199(6):837-846
7. Kartau M, Auvinen E, Verkkoniemi-Ahola A, et al. JC polyomavirus DNA detection in clinical practice. J Clin Virol. 2022;146:105051. doi:10.1016/j.jcv.2021.105051
Viral nucleic acid is extracted from the specimen using the MagNA Pure automated instrument (Roche Applied Science). Primers are directed to the large T antigen gene, which is a conserved sequence specific for JC virus (JCV). This assay detects only JCV; it does not detect BK virus or Simian virus 40 (SV40) (other polyomaviruses). The LightCycler instrument (Roche Applied Science) amplifies and monitors the development of target nucleic acid sequences after the annealing step during polymerase chain reaction (PCR) cycling. This automated PCR system can rapidly detect amplicon development through stringent air-controlled temperature cycling in capillary cuvettes. The detection of amplified products is based on the fluorescence resonance energy transfer (FRET) principle. For FRET product detection, a hybridization probe with a donor fluorophore, fluorescein, on the 3'-end is excited by an external light source and emits light that is absorbed by a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5'-end. The acceptor fluorophore then emits a light of a different wavelength that can be measured with a signal that is proportional to the amount of specific PCR product.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
87798
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
JCPCR | JC Virus, PCR, CSF | 33295-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
618305 | JC Virus, PCR, CSF | 33295-7 |